June 30, 2025
Learn how to parse SEC Form D filings into a private capital database for biotech and venture research.
Scientific Analysis of Biotechnology Companies
Technical evaluation of therapeutic programs and drug discovery platforms
Most biotech analysts focus on what companies say. We focus on what they do.
RxDataLab examines biotechnology companies by analyzing clinical trials, regulatory filings, patents, hiring patterns, and technical documents. Our focus is on therapeutic development programs, devices, and platform technologies—especially those in neuroscience and AI-driven drug discovery.
We combine domain expertise in neuroscience with systematic analysis of public data to assess scientific validity, competitive positioning, and operational progress. Our research helps investors and operators understand what’s real, what’s likely, and what to watch next.
Stay Informed
Subscribe for research and analysis on emerging biotechnology and pharmaceutical developments.
Recent Analysis
View allJune 22, 2025
Eikon Therapeutics has raised over $1B and claims to have a revolutionary drug discovery platform, but its clinical pipeline remains dominated by acquired oncology assets. This report analyzes Eikon’s funding, trials, and patent strategy to assess whether its platform is delivering.
June 10, 2025
After Lundbeck’s $2B acquisition of Longboard, investors scrambled for serotonin analogs. Here’s why Bright Minds was the target and what it says about the future of rare epilepsy drug development.
What We Analyze
Clinical Development
Trial design, endpoints, timelines, and regulatory strategy
Intellectual Property
Patent landscapes, filing strategies, and expiration risks
Scientific Validation
Publications, mechanism consistency, and platform claims
Operational Signals
Hiring patterns, regulatory activity, and business development